Survivin-targeted immune cell therapy for new glioblastoma
Part of Cancer clinical trials.
This trial tests a personalized immune therapy made from your own cells (dendritic cells) that target a protein called survivin in glioblastoma. It's given after standard radiation and chemotherapy, and may help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old and have been newly diagnosed with glioblastoma (a type of brain cancer).
- Your tumor has a protein called survivin, which this treatment targets.
- You have had surgery to remove most of the tumor and are healthy enough to do daily activities (KPS score 70+).
- You have completed initial radiation and chemotherapy (temozolomide) without the cancer getting worse.
- You are willing to avoid other cancer treatments during the study and can have a procedure to collect white blood cells (apheresis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy called PERCELLVAC-Sur that targets a protein (Survivin) found in glioblastoma tumors. It is given after standard radiation and chemotherapy, and the goal is to see if it helps the immune system fight the cancer more effectively.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to treat glioblastoma that has come back after standard treatment. The vaccine is designed to help your immune system recognize and attack your tumor.
This trial tests whether adding a personalized vaccine made from your own immune cells and tumor can help standard chemotherapy and radiation work better against glioblastoma. It is for patients who have already had surgery and are starting or have just finished their first round of chemoradiation.
This trial tests a personalized vaccine made from your own immune cells to see if it can help treat glioblastoma. If you are currently getting standard treatments like surgery, chemo, and radiation, you may be able to join.
This trial tests a personalized vaccine (made from your own immune cells and tumor 'neoantigens') combined with the chemotherapy drug temozolomide for people with newly diagnosed glioblastoma. The goal is to see if adding the vaccine helps the immune system better fight the tumor.
This trial tests a new approach using immune cells called cytokine-induced killer cells to treat glioblastoma. It aims to find the best way to prepare these cells to fight the tumor.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.